Core Deferred Long Term Liab from 2010 to 2024
| CLB Stock | USD 20.55 0.29 1.39% |
Deferred Long Term Liabilities | First Reported 2010-06-30 | Previous Quarter 54.7 M | Current Value 52 M | Quarterly Volatility 15.3 M |
Check Core Laboratories financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Core Laboratories' main balance sheet or income statement drivers, such as Depreciation And Amortization of 19.2 M, Interest Expense of 10.1 M or Selling General Administrative of 34.6 M, as well as many indicators such as Price To Sales Ratio of 2.7, Dividend Yield of 0.0022 or PTB Ratio of 6.42. Core financial statements analysis is a perfect complement when working with Core Laboratories Valuation or Volatility modules.
Core | Deferred Long Term Liab |
Latest Core Laboratories' Deferred Long Term Liab Growth Pattern
Below is the plot of the Deferred Long Term Liab of Core Laboratories NV over the last few years. It is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. Core Laboratories' Deferred Long Term Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Core Laboratories' overall financial position and show how it may be relating to other accounts over time.
| Deferred Long Term Liab | 10 Years Trend |
|
Deferred Long Term Liab |
| Timeline |
Core Deferred Long Term Liab Regression Statistics
| Arithmetic Mean | 48,162,272 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 39.89 | |
| Mean Deviation | 14,126,848 | |
| Median | 52,528,000 | |
| Standard Deviation | 19,212,858 | |
| Sample Variance | 369.1T | |
| Range | 77.8M | |
| R-Value | 0.62 | |
| Mean Square Error | 242.8T | |
| R-Squared | 0.39 | |
| Significance | 0.01 | |
| Slope | 2,679,853 | |
| Total Sum of Squares | 5167.9T |
Core Deferred Long Term Liab History
About Core Laboratories Financial Statements
Core Laboratories stakeholders use historical fundamental indicators, such as Core Laboratories' Deferred Long Term Liab, to determine how well the company is positioned to perform in the future. Although Core Laboratories investors may analyze each financial statement separately, they are all interrelated. For example, changes in Core Laboratories' assets and liabilities are reflected in the revenues and expenses on Core Laboratories' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Core Laboratories NV. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Deferred Long Term Liabilities | 62.9 M | 51.5 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Core Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Core Laboratories' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Core Laboratories Nv Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Core Laboratories Nv Stock:Check out the analysis of Core Laboratories Correlation against competitors. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Oil & Gas Equipment & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Core Laboratories. If investors know Core will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Core Laboratories listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.316 | Dividend Share 0.04 | Earnings Share 0.54 | Revenue Per Share 11.158 | Quarterly Revenue Growth 0.072 |
The market value of Core Laboratories is measured differently than its book value, which is the value of Core that is recorded on the company's balance sheet. Investors also form their own opinion of Core Laboratories' value that differs from its market value or its book value, called intrinsic value, which is Core Laboratories' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Core Laboratories' market value can be influenced by many factors that don't directly affect Core Laboratories' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Core Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine if Core Laboratories is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Core Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.